IRIS
DEL MASTRO, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 28.873
AS - Asia 4.331
NA - Nord America 3.057
SA - Sud America 368
AF - Africa 114
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 2
Totale 36.761
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 27.797
US - Stati Uniti d'America 2.890
SG - Singapore 1.730
CN - Cina 1.107
VN - Vietnam 701
FR - Francia 329
BD - Bangladesh 309
FI - Finlandia 276
BR - Brasile 229
HK - Hong Kong 184
DE - Germania 131
NL - Olanda 82
GB - Regno Unito 68
CA - Canada 67
AR - Argentina 62
JP - Giappone 58
ES - Italia 47
MX - Messico 47
IN - India 39
ID - Indonesia 27
IQ - Iraq 27
RU - Federazione Russa 26
CH - Svizzera 24
MW - Malawi 23
EC - Ecuador 21
PH - Filippine 21
ZA - Sudafrica 17
AU - Australia 16
CL - Cile 16
CO - Colombia 15
EG - Egitto 14
SA - Arabia Saudita 14
TR - Turchia 14
IE - Irlanda 13
JM - Giamaica 13
AT - Austria 11
BE - Belgio 11
DZ - Algeria 11
KE - Kenya 11
MA - Marocco 11
PK - Pakistan 11
TH - Thailandia 11
PY - Paraguay 10
SE - Svezia 10
MY - Malesia 8
UZ - Uzbekistan 8
CR - Costa Rica 7
KR - Corea 7
LB - Libano 7
PL - Polonia 7
TW - Taiwan 7
NP - Nepal 6
RO - Romania 6
UA - Ucraina 6
VE - Venezuela 6
GT - Guatemala 5
HN - Honduras 5
DO - Repubblica Dominicana 4
JO - Giordania 4
NI - Nicaragua 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CG - Congo 3
CI - Costa d'Avorio 3
IL - Israele 3
IR - Iran 3
KW - Kuwait 3
KZ - Kazakistan 3
PT - Portogallo 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AM - Armenia 2
AZ - Azerbaigian 2
BB - Barbados 2
BG - Bulgaria 2
BO - Bolivia 2
BS - Bahamas 2
BY - Bielorussia 2
CU - Cuba 2
ET - Etiopia 2
HR - Croazia 2
KH - Cambogia 2
LT - Lituania 2
LY - Libia 2
NO - Norvegia 2
OM - Oman 2
PE - Perù 2
PR - Porto Rico 2
SI - Slovenia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AO - Angola 1
BJ - Benin 1
BW - Botswana 1
CY - Cipro 1
CZ - Repubblica Ceca 1
Totale 36.738
Salva come PNG Salva come JPEG
Città #
Genova 12.582
Genoa 9.890
Rapallo 2.503
Vado Ligure 2.270
Singapore 838
San Jose 752
Ashburn 456
Council Bluffs 284
Lauterbourg 284
Helsinki 256
Ho Chi Minh City 208
Beijing 183
Hong Kong 174
New York 169
Hanoi 152
Santa Clara 102
Bordighera 95
Frankfurt am Main 89
Boardman 81
Los Angeles 53
Tokyo 51
Amsterdam 46
Milan 41
Chicago 33
Haiphong 33
Buffalo 32
Da Nang 29
Mexico City 28
São Paulo 28
Rome 27
Orem 26
Naples 24
Tianjin 22
Boston 20
Lappeenranta 18
Atlanta 16
Bologna 16
Zurich 16
Dallas 15
Guangzhou 15
Madrid 15
Barcelona 14
Hải Dương 14
Toronto 14
Dublin 13
Schiffdorf 13
City of London 12
Curitiba 12
Houten 12
Phủ Lý 12
Shenzhen 12
Des Moines 11
Phoenix 11
St Louis 11
Baghdad 10
Enfield 10
Houston 10
Melbourne 10
Montreal 10
Shanghai 10
Turin 10
Biên Hòa 9
Palermo 9
Piscataway 9
Seattle 9
Brescia 8
Miami 8
Nairobi 8
Santiago 8
Tashkent 8
Venice 8
Agawam 7
Bangkok 7
Bari 7
Cairo 7
Denver 7
Florence 7
Jakarta 7
Jeddah 7
Johannesburg 7
Kingston 7
Paris 7
Philadelphia 7
Quito 7
Salt Lake City 7
San Francisco 7
Stockholm 7
Thái Bình 7
Vĩnh Long 7
Bắc Giang 6
Chongqing 6
Fontaine-l'Évêque 6
London 6
Mumbai 6
Nuremberg 6
Orlando 6
Riyadh 6
Thái Nguyên 6
Washington 6
Asunción 5
Totale 32.478
Salva come PNG Salva come JPEG
Nome #
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† 425
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 292
Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. 241
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 239
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis 234
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 222
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) 209
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 205
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 201
Cancer and fertility preservation: international recommendations from an expert meeting 200
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 197
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 193
Management of young women with early breast cancer 192
Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies 190
State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature 184
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 184
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence 183
Circulating tumor DNA using tagged targeted deep sequencing to assess minimal residual disease in breast cancer patients undergoing neoadjuvant chemotherapy 183
Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients 182
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of Fc gamma RIIIA/Fc gamma RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 180
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial 179
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer 179
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 177
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 177
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 176
The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients 175
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate? 175
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 173
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 172
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data 171
Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence 167
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 167
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 167
Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes 166
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 164
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study 164
A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes 164
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 164
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 164
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 162
Treatment with aromatase inhibitors and markers of cardiovascular disease 161
News on the medical treatment of young women with early-stage HER2-negative breast cancer 161
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials 161
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 161
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients 161
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 161
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 160
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 159
Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology 159
Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. 159
Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer 157
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 156
Pharmacotherapy to protect ovarian function and fertility during cancer treatment 156
Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence 156
Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity 156
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 156
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients 155
Taxane-containing chemotherapy in the treatment of early breast cancer patients 154
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial 153
Targeting bone metastatic cancer: Role of the mTOR pathway 153
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study 152
Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study 152
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 152
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients 152
Optimization of a wga-free molecular tagging-based ngs protocol for ctcs mutational profiling 152
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole 152
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group 151
A case where switching end points for clinical trial interpretation might be the right choice 150
Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells 150
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. 150
Letrozole withdrawal response in locally advanced breast cancer 149
Exploring the safety of chemotherapy for treating breast cancer during pregnancy 149
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 149
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis 148
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 148
Predicting mood disorders in breast cancer patients. 147
Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives 147
Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer 146
Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations 146
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 145
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 144
Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? 144
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 144
Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system’s inhibitor denosumab vs. bisphosphonates 143
Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis 143
Anthracycline-free therapy for HER2-amplified breast cancer 142
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors 142
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy 142
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 142
Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study 142
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer 142
Fertility, sexuality and cancer in young adult women 141
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients 140
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy 140
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 139
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival A Randomized Clinical Trial 138
Reply to the letter to the editor 'Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?' by Rodriguez-Wallberg et al. 137
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 137
Randomized cooperative study of perioperative chemotherapy in breast cancer. 136
Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients 136
Totale 16.695
Salva come PNG Salva come JPEG
Categoria #
all - tutte 130.617
article - articoli 130.364
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 253
Totale 261.234
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021176 0 0 0 0 0 0 0 0 0 0 0 176
2021/20222.704 142 108 128 261 73 302 97 616 279 247 96 355
2022/20233.079 274 249 31 283 448 457 79 379 507 27 305 40
2023/20241.831 72 227 55 250 145 191 127 154 80 106 110 314
2024/20255.998 194 442 159 382 725 711 494 956 295 340 594 706
2025/202613.739 1.232 517 1.623 1.154 1.594 1.017 1.997 710 1.029 1.450 1.014 402
Totale 37.957